TCGA-GU-A762-01A-11R-A33J-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 7.621550591
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.710
- INTERFERON_GAMMA_RESPONSE+0.600
- ALLOGRAFT_REJECTION+0.580
- IL6_JAK_STAT3_SIGNALING+0.530
- E2F_TARGETS+0.440
- INFLAMMATORY_RESPONSE+0.430
- MYC_TARGETS_V2+0.430
- COAGULATION+0.420
- DNA_REPAIR+0.410
- COMPLEMENT+0.400
Top 10 suppressed
- PEROXISOME-0.180
- ESTROGEN_RESPONSE_EARLY-0.150
- HYPOXIA-0.120
- KRAS_SIGNALING_DN-0.120
- SPERMATOGENESIS-0.090
- UV_RESPONSE_DN-0.090
- MYOGENESIS-0.080
- PROTEIN_SECRETION-0.070
- BILE_ACID_METABOLISM-0.050
- CHOLESTEROL_HOMEOSTASIS-0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-FD-A6TD-01A-51R-A33J-07 | — | — | 0.916 |
| 2 | 25B5E54F-5858-454C-9B23-440A82450912 | — | — | 0.897 |
| 3 | SRR1516056 | — | — | 0.893 |
| 4 | SRR1516055 | — | — | 0.893 |
| 5 | TCGA-ZF-A9RD-01A-11R-A42T-07 | — | — | 0.890 |
| 6 | R209 | — | — | 0.889 |
| 7 | TCGA-DK-AA6M-01A-11R-A39I-07 | — | — | 0.886 |
| 8 | TCGA-XF-A9SM-01A-11R-A42T-07 | — | — | 0.884 |
| 9 | TCGA-UY-A9PB-01A-11R-A38B-07 | — | — | 0.877 |
| 10 | TCGA-66-2765-01A-01R-0851-07 | — | cohortSQ1 | 0.874 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.710 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.580 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.530 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.430 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.430 | Idelalisib | — uncovered |
| COAGULATION | 0.420 | Binimetinib | — uncovered |
| DNA_REPAIR | 0.410 | Idelalisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.390 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.380 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.350 | Inavolisib | — uncovered |
| APOPTOSIS | 0.320 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.270 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.260 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.250 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.240 | Inavolisib | — uncovered |